1. Home
  2. LGND vs CURB Comparison

LGND vs CURB Comparison

Compare LGND & CURB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGND
  • CURB
  • Stock Information
  • Founded
  • LGND 1987
  • CURB 2024
  • Country
  • LGND United States
  • CURB United States
  • Employees
  • LGND 68
  • CURB N/A
  • Industry
  • LGND Biotechnology: Pharmaceutical Preparations
  • CURB
  • Sector
  • LGND Health Care
  • CURB
  • Exchange
  • LGND Nasdaq
  • CURB NYSE
  • Market Cap
  • LGND 2.2B
  • CURB 2.4B
  • IPO Year
  • LGND 1992
  • CURB N/A
  • Fundamental
  • Price
  • LGND $139.02
  • CURB $22.95
  • Analyst Decision
  • LGND Strong Buy
  • CURB Buy
  • Analyst Count
  • LGND 8
  • CURB 7
  • Target Price
  • LGND $144.71
  • CURB $26.29
  • AVG Volume (30 Days)
  • LGND 139.7K
  • CURB 557.9K
  • Earning Date
  • LGND 08-05-2025
  • CURB 07-28-2025
  • Dividend Yield
  • LGND N/A
  • CURB 2.77%
  • EPS Growth
  • LGND N/A
  • CURB N/A
  • EPS
  • LGND N/A
  • CURB 0.11
  • Revenue
  • LGND $181,488,000.00
  • CURB $131,537,000.00
  • Revenue This Year
  • LGND $18.41
  • CURB $34.07
  • Revenue Next Year
  • LGND $18.87
  • CURB $13.12
  • P/E Ratio
  • LGND N/A
  • CURB $210.04
  • Revenue Growth
  • LGND 53.40
  • CURB 31.90
  • 52 Week Low
  • LGND $81.74
  • CURB $18.80
  • 52 Week High
  • LGND $129.90
  • CURB $25.69
  • Technical
  • Relative Strength Index (RSI)
  • LGND 75.81
  • CURB N/A
  • Support Level
  • LGND $120.68
  • CURB N/A
  • Resistance Level
  • LGND $126.24
  • CURB N/A
  • Average True Range (ATR)
  • LGND 4.48
  • CURB 0.00
  • MACD
  • LGND 1.87
  • CURB 0.00
  • Stochastic Oscillator
  • LGND 96.06
  • CURB 0.00

About LGND Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

About CURB CURBLINE PPTYS CORP

Curbline Properties Corp is engaged in the business of owning, managing, leasing and acquiring a portfolio of convenience shopping centers. The primary source of the Company's income is generated from the rental of the Company's convenience shopping centers to tenants. Convenience shopping centers are generally positioned on the curbline of well-trafficked intersections and major vehicular corridors, offering excellent access and visibility, dedicated parking and often include drive-thru units, with approximately half of Curbline properties having at least one drive-thru unit.

Share on Social Networks: